Greenwich LifeSciences, Inc.
NASDAQ Capital MarketTotal Valuation
Greenwich LifeSciences, Inc. carries a market capitalization of 303.49M, placing it among publicly traded companies globally.
| Market Cap | 303.49M |
| Enterprise Value | N/A |
Share Statistics
Greenwich LifeSciences, Inc. currently has 14.67M shares outstanding.
| Shares Outstanding | 14.67M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -3.59 |
| P/TBV Ratio | 63.17 |
| P/FCF Ratio | -26.05 |
| P/OCF Ratio | -26.05 |
Financial Position
Greenwich LifeSciences, Inc. maintains a current ratio of 2.01, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.01 |
| Quick Ratio | 2.01 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -328.25 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Greenwich LifeSciences, Inc.'s stock has gained approximately 105.32572% over the past 52 weeks. The 50-day moving average sits at 24.13, while the 200-day moving average is 19.69.
| Beta (5Y) | N/A |
| 52-Week Price Change | 105.32572% |
| 50-Day Moving Average | 24.13 |
| 200-Day Moving Average | 19.69 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -21.89M, while operating income came in at -21.89M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -21.89M |
| Pretax Income | -21.76M |
| Net Income | -21.76M |
| EBITDA | -21.89M |
| EBIT | -21.89M |
| Earnings Per Share (EPS) | -1.57 |
Balance Sheet
Total book value stands at -92.78M, with working capital of 5.27M providing operational flexibility.
| Cash & Cash Equivalents | 10.51M |
| Total Debt | N/A |
| Net Debt | -10.51M |
| Equity (Book Value) | -92.78M |
| Book Value Per Share | -6.69 |
| Working Capital | 5.27M |
Cash Flow
Greenwich LifeSciences, Inc. produced -12.78M in operating cash flow over the past twelve months.
| Operating Cash Flow | -12.78M |
| Capital Expenditures | N/A |
| Free Cash Flow | -12.78M |
| FCF Per Share | -0.92 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -6.17 |
| FCF Yield | -3.84 |
Scores
Greenwich LifeSciences, Inc. posts an Altman Z-Score of 19.51, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 19.51 |